Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.68 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035344 | 0.98 | LTA4H (0.66) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL13176582 | 0.86 | CYP1A2 (0.65) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL12324532 | 0.86 | CYP1A2 (0.65) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL10529024 | 0.86 | CYP1A2 (0.65) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL7179523 | 0.85 | BLM (0.65) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL16330413 | 0.85 | BLM (0.65) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL233498 | 0.84 | CYP1A2 (0.70) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL1679787 | 0.84 | LTA4H (0.48) | LTA4HGABRR1CYP1A2BLMALOX15 | |
| SCHEMBL25923088 | 0.84 | CYP1A2 (0.70) | LTA4HGABRR1CYP1A2BLMACE2 | |
| SCHEMBL1193585 | 0.84 | LTA4H (0.59) | LTA4HGABRR1CYP1A2BLMACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448607-A1 | COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS | Biosyntech Canada Inc. (CA) | 2004-08-25 | — | — | EP | claimed |
| WO-2003042250-A1 | COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS | BIOSYNTECH CANADA INC. (CA) | 2003-05-22 | — | — | WO | claimed |
| EP-2303920-A2 | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES | Abbott Laboratories (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010011947-A2 | AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES | ABBOTT LABORATORIES (US) | 2010-01-28 | — | — | WO | disclosed |
| US-5310880-A | Chromatography, alkali halide, acid solution | THE GENERAL HOSPITAL CORPORATION (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1992018145-A1 | PURIFICATION OF MÜLLERIAN INHIBITING SUBSTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |